Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
218.06
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
37
38
Next >
Can These 2 Stocks Crush the Market Again in 2023?
December 04, 2022
Both are riding the wave of major clinical wins
Via
The Motley Fool
Is Biogen Stock a Buy Now?
December 04, 2022
Its revenue now has a plausible path to doubling, but risks remain high.
Via
The Motley Fool
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
December 02, 2022
The S&P 500 is fighting for its 200-day, a critical level for the uptrend.
Via
Investor's Business Daily
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
November 30, 2022
Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD).
Via
Benzinga
CrowdStrike (CRWD) Stock Sinks on Weak Guidance
November 30, 2022
CrowdStrike (CRWD) stock is falling on Wednesday following the release of its earnings report for the third quarter of 2022.
Via
InvestorPlace
26 Analysts Have This to Say About Biogen
November 30, 2022
Via
Benzinga
BIIB Stock Alert: What the Latest Alzheimer’s Drug Data Means for Biogen
November 30, 2022
Biogen (BIIB) stock is on the move Wednesday after the company provided the latest update on its Alzheimer's drug candidate.
Via
InvestorPlace
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
November 30, 2022
Via
Benzinga
Biogen Stock Is Surging Today: What's Going On?
November 30, 2022
Biogen Inc (NASDAQ: BIIB) shares are trading higher Wednesday after the company announced positive trial results for its experimental Alzheimer's
Via
Benzinga
Alphabet To $135? Here Are 10 Other Price Target Changes For Wednesday
November 30, 2022
Mizuho cut Alphabet Inc. (NASDAQ: GOOGL) price target from $140 to $135. Mizuho analyst James Lee maintained a Buy rating on the stock. Alphabet shares gained 0.4% to $95.53 in pre-market trading.
Via
Benzinga
Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors
November 29, 2022
The update from Eisai suggests there is a benefit question ahead of the companies.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
November 28, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success
November 28, 2022
Biogen and Axsome stocks diverged Monday on news out of their Alzheimer's studies.
Via
Investor's Business Daily
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
November 28, 2022
A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that...
Via
Benzinga
Market Currents: Why Pick Stocks?
November 28, 2022
Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and...
Via
Talk Markets
2 Stocks Near 52-Week Highs That Could Climb Higher
November 28, 2022
This pair of stocks are bucking the trend and they could climb even higher.
Via
The Motley Fool
CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention
November 23, 2022
By Jad Malaeb, Benzinga
Via
News Direct
Topics
ETFs
Economy
Exposures
Interest Rates
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
November 23, 2022
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.
Via
Benzinga
CBOE's Weekly Market Recap: Nov.14-18 – Biogen's Alzheimer's Drug Captures Investors' Attention
November 23, 2022
The market has experienced some relief from bearish price action in November, continuing October’s push to usher the SPDR S&P 500 ETF (NYSEARCA: SPY) toward $400.
Via
Benzinga
Not All Offices Are Created Equal… You Can Profit From One Sector That’s Poised to See Demand Growth
November 22, 2022
Despite what we might see in the upcoming year with office real estate or specific companies within the life sciences industry, REITs with exposure to in-demand properties remain a great way to earn...
Via
Talk Markets
TEVA Stock Alert: What to Know About Teva Pharmaceuticals’ New CEO
November 21, 2022
Teva Pharmaceuticals (TEVA) stock is sliding on Monday after the company announced Richard Francis as its newest president and CEO.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
November 17, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
3 Stocks to Avoid Right Now
November 17, 2022
Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.
Via
The Motley Fool
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
November 16, 2022
Neurodegenerative disorders could mean big bucks for some biotechs.
Via
Investor's Business Daily
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
November 15, 2022
Via
Benzinga
Why Is Cassava Sciences (SAVA) Stock Up Today?
November 14, 2022
Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever.
Via
InvestorPlace
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
November 14, 2022
Via
Benzinga
Why Is AST SpaceMobile (ASTS) Moving Today?
November 14, 2022
AST SpaceMobile (ASTS) stock is a hot topic on Monday as investors react to the company setting up its BlueWalker 3 satellite array.
Via
InvestorPlace
Why Is Biogen (BIIB) Stock Up Today?
November 14, 2022
Biogen (BIIB) stock is rising higher on Monday after Roche's (RHHBY) Alzheimer's drug didn't perform well in a clinical trial.
Via
InvestorPlace
What's Going On With Biogen Stock Today?
November 14, 2022
Biogen Inc (NASDAQ: BIIB) shares are trading higher Monday after competitor Roche's Alzheimer's candidate did not meet its primary endpoint in recent studies.
Via
Benzinga
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.